Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors — Philippe A. Cassier (2025) | RDL Network
Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors
Article 2025 en
Authors
PC
Philippe A. Cassier
MB
Mitesh J. Borad
SS
Sunil Sharma
Abstract
1 min read
TRK-950, a humanized antibody targeting CAPRIN-1, demonstrated good tolerability, no dose-limiting toxicities, a favorable PK profile, and potential antitumor activity in this first-in-human study. Currently, TRK-950 is undergoing Phase Ib and II trials for various cancers, showing promising development potential.
Discussion(0)
No comments yet. Be the first to comment.